Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
Type:
Grant
Filed:
April 30, 2013
Date of Patent:
March 24, 2015
Assignee:
MedImmune, LLC
Inventors:
Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
Abstract: The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual.
Type:
Grant
Filed:
April 26, 2013
Date of Patent:
March 17, 2015
Assignee:
The Regents of the University of California
Inventors:
David V. Schaffer, Kevin Edward Healy, Lauren Little, Patrick Sean Daugherty
Abstract: The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of Leishmania.
Type:
Grant
Filed:
May 27, 2014
Date of Patent:
March 3, 2015
Assignee:
Universidade Federal de Minas Gerais—UFMG
Inventors:
Ana Paula Salles Moura Fernandes, Christiane De Freitas Abrantes, Eduardo Antonio Ferraz Coelho, Ricardo Tostes Gazzinelli
Abstract: The current invention pertains to an aqueous composition containing a biological antigen and an acrylic acid polymer, wherein the composition comprises an electrolyte to provide an osmolarity higher than the osmolarity of a 0.9% (w/v) sodium chloride solution in water. The invention also pertains to the acrylic acid polymer for use in a one shot vaccine against porcine circo virus 2 (PCV2) and optionally Mycoplasma hyopneumoniae and in an aqueous composition for reducing fever induced by the biological antigens present in the aqueous composition when the composition is administered to a subject animal.
Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.
Abstract: Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a veterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. pseudomallei-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. pseudomallei-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. pseudomallei, such as meliodosis.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
February 24, 2015
Assignee:
Board of Regents of the Nevada System of Higher Education
Inventors:
David P. AuCoin, Thomas R. Kozel, Claire Smalley
Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
Abstract: The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.
Type:
Grant
Filed:
September 25, 2009
Date of Patent:
February 24, 2015
Assignee:
The Regents of the University of Michigan
Inventors:
James R. Baker, Jr., Mark R. Hemmila, Stewart C. Wang, Tarek Hamouda, John J. LiPuma, Jessica A. Knowlton, Paul E. Makidon, Luz P. Blanco, Jeffery V. Groom, II, Anna U. Bielinska
Abstract: A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route.
Type:
Grant
Filed:
September 5, 2014
Date of Patent:
February 24, 2015
Assignee:
National University Corporation Tokyo Medical and Dental University
Abstract: Embodiments of the presently-disclosed subject matter provide an isolated polypeptide comprising the sequence of SEQ ID NO: 1, fragments thereof, and/or epitopes thereof. Embodiments of the presently-disclosed subject matter also provide methods for diagnosing a Strongylus vulgaris infection in a subject that comprises providing a biological sample from the subject and contacting the sample with the present isolated polypeptide, fragment thereof, and/or epitope thereof. In some embodiments the Strongylus vulgaris infection can be detected during a prepatent period. In further embodiments the subject is a horse.
Type:
Grant
Filed:
October 29, 2013
Date of Patent:
February 10, 2015
Assignee:
University of Kentucky Research Foundation
Inventors:
Martin Nielsen, Ulla Anderson, Daniel Howe
Abstract: A method for diagnosing Lyme disease status in a mammal is provided. The method entails, in a biological sample obtained or derived from a mammal, determining antibodies to Borrelia burgdorferi (B. burgdorferi) outer surface proteins (Osp) OspA, OspC, and OspF. Based upon determining the OspA, OspC, and OspF antibodies, the mammal can be diagnosed as vaccinated, not vaccinated, infected or not infected with B. burgdorferi. Mammals that have early, intermediate or chronic B. burgdorferi infection can also be identified. The method is particularly suited for use with horses and dogs. Isolated or recombinant B. burgdorferi antigens and compositions that contain them are also provided.
Abstract: A non-treponemal diagnostic test for syphilis infection includes initially dissolving cholesterol in an organic solvent and further diluting the dissolved cholesterol in an ethanol solution comprising cardiolipin and lecithin, permitting a volume of the antigen solution to evaporate in place within a container, rinsing the coated container with buffered saline, stabilizing the antigen coating by overcoating the antigen coating with an inert protein dissolved in buffered saline, decanting the overcoat solution, air-drying the container, and sealing the container in vapor-proof pouches with desiccant, providing an enzyme-labeled conjugate component of a syphilis infection test that is formulated to be compatible with a lipid nature of the cholesterol, the cardiolipin, and the lecithin VDRL antigens, providing a sample diluent that is formulated to be compatible with the lipid nature of the VDRL antigens, and providing a wash fluid that is formulated to be compatible with the lipid nature of the VDRL antigens.
Abstract: A highly sensitive method of analyzing a sample for the presence or activity of botulinum neurotoxin (BoNT) or antibodies specific for botulinum neurotoxin is disclosed. In one embodiment, the method comprises the steps of preparing primary non-human mammalian or avian spinal cord cells, and exposing the cells to a test sample, in parallel with a control sample, and examining the extent of cleavage of the intracellular neuronal target protein in both the test and control sample.
Type:
Grant
Filed:
November 10, 2008
Date of Patent:
January 27, 2015
Assignees:
Wisconsin Alumni Research Foundation
Inventors:
Eric A. Johnson, Sabine Pellett, William H. Tepp, Gary E. Borodic, David J. Beebe, Amy Paguirigan
Abstract: The present invention provides a one phase, aqueous vaccine composition for immunizing an animal against infection by Mycoplasma hyopneumoniae, comprising: an immunizing amount of a Mycoplasma hyopneumoniae bacterin, an acrylic acid polymer in the concentration range between 0.8 and 1.2 mg/ml, and a pharmaceutically acceptable carrier, and substantially no oil. It is especially useful for immunizing a pig against infection by Mycoplasma hyopneumoniae for at least 20 weeks after a single administration, which effective immunity is reached within 4 weeks after vaccination.
Type:
Grant
Filed:
September 4, 2014
Date of Patent:
January 27, 2015
Assignee:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
William Charles Ohnesorge, Isabelle Freiin Von Richthofen, Marika Christine Genzow, Martina Von Freyburg, Carola Kissel, Luc-Etienne Fabry, Knut Elbers, Kathleen Kwan Young Park
Abstract: A cell based assay for detection for protease activity is disclosed. In the assay a cell is engineered to express a protease substrate with at least one label, preferably on its C-terminus. Cleavage of the substrate by the protease that recognizes it results in a C-terminal fragment and a N-terminal fragment, where the fragment having the label is subject to ubiquitin proteasome degradation. The assay measures the disappearance of the label due to degradation of the fragment to which it is attached. A cell free assay is also described for detection of protease activity. In the cell free assay, the protease substrate is expressed in a solution that includes the elements of the ubiquitin proteasome pathway for degradation of the fragment. The assay measures the disappearance of the label attached to the fragment that results from cleavage by the protease.
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
February 28, 2012
Date of Patent:
January 13, 2015
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently convert carbon dioxide and light into n-alkanes, and in particular the use of such organisms for the commercial production of n-alkanes and related molecules.
Type:
Grant
Filed:
April 9, 2012
Date of Patent:
January 13, 2015
Assignee:
Joule Unlimited Technologies, Inc.
Inventors:
Nikos Basil Reppas, Christian Perry Ridley
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
January 5, 2012
Date of Patent:
January 6, 2015
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: Disclosed herein are methods for quickly obtaining crude membranes from cells, including animal and plant cells. The methods include incubating cells in a buffer and forcing the cells through a filter that causes rupture of the cells, and then separating the resulting crude membranes from most cytosolic proteins.